DO
Therapeutic Areas
Alcresta Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RELiZORB | Fat malabsorption in enterally fed patients (e.g., cystic fibrosis, short bowel syndrome) | Phase 3 |
| RELiZORB Pediatric Registry | Observational data collection in pediatric GI patients | Registry |